% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Haack:138289,
author = {Haack, Tobias B and Jackson, Christopher B and Murayama,
Kei and Kremer, Laura S and Schaller, André and
Kotzaeridou, Urania and de Vries, Maaike C and Schottmann,
Gudrun and Santra, Saikat and Büchner, Boriana and Wieland,
Thomas and Graf, Elisabeth and Freisinger, Peter and
Eggimann, Sandra and Ohtake, Akira and Okazaki, Yasushi and
Kohda, Masakazu and Kishita, Yoshihito and Tokuzawa, Yoshimi
and Sauer, Sascha and Memari, Yasin and Kolb-Kokocinski,
Anja and Durbin, Richard and Hasselmann, Oswald and Cremer,
Kirsten and Albrecht, Beate and Wieczorek, Dagmar and
Engels, Hartmut and Hahn, Dagmar and Zink, Alexander M and
Alston, Charlotte L and Taylor, Robert W and Rodenburg,
Richard J and Trollmann, Regina and Sperl, Wolfgang and
Strom, Tim M and Hoffmann, Georg F and Mayr, Johannes A and
Meitinger, Thomas and Bolognini, Ramona and Schuelke, Markus
and Nuoffer, Jean-Marc and Kölker, Stefan and Prokisch,
Holger and Klopstock, Thomas},
title = {{D}eficiency of {ECHS}1 causes mitochondrial encephalopathy
with cardiac involvement.},
journal = {Annals of Clinical and Translational Neurology},
volume = {2},
number = {5},
issn = {2328-9503},
address = {Chichester [u.a.]},
publisher = {Wiley},
reportid = {DZNE-2020-04611},
pages = {492-509},
year = {2015},
abstract = {Short-chain enoyl-CoA hydratase (ECHS1) is a
multifunctional mitochondrial matrix enzyme that is involved
in the oxidation of fatty acids and essential amino acids
such as valine. Here, we describe the broad phenotypic
spectrum and pathobiochemistry of individuals with
autosomal-recessive ECHS1 deficiency.Using exome sequencing,
we identified ten unrelated individuals carrying compound
heterozygous or homozygous mutations in ECHS1. Functional
investigations in patient-derived fibroblast cell lines
included immunoblotting, enzyme activity measurement, and a
palmitate loading assay.Patients showed a heterogeneous
phenotype with disease onset in the first year of life and
course ranging from neonatal death to survival into
adulthood. The most prominent clinical features were
encephalopathy (10/10), deafness (9/9), epilepsy (6/9),
optic atrophy (6/10), and cardiomyopathy (4/10). Serum
lactate was elevated and brain magnetic resonance imaging
showed white matter changes or a Leigh-like pattern
resembling disorders of mitochondrial energy metabolism.
Analysis of patients' fibroblast cell lines (6/10) provided
further evidence for the pathogenicity of the respective
mutations by showing reduced ECHS1 protein levels and
reduced 2-enoyl-CoA hydratase activity. While serum
acylcarnitine profiles were largely normal, in vitro
palmitate loading of patient fibroblasts revealed increased
butyrylcarnitine, unmasking the functional defect in
mitochondrial β-oxidation of short-chain fatty acids.
Urinary excretion of 2-methyl-2,3-dihydroxybutyrate - a
potential derivative of acryloyl-CoA in the valine catabolic
pathway - was significantly increased, indicating impaired
valine oxidation.In conclusion, we define the phenotypic
spectrum of a new syndrome caused by ECHS1 deficiency. We
speculate that both the β-oxidation defect and the block in
l-valine metabolism, with accumulation of toxic
methacrylyl-CoA and acryloyl-CoA, contribute to the disorder
that may be amenable to metabolic treatment approaches.},
cin = {Ext HZM / AG Levin},
ddc = {610},
cid = {I:(DE-2719)5000050 / I:(DE-2719)1111016},
pnm = {342 - Disease Mechanisms and Model Systems (POF3-342) / 344
- Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-342 / G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26000322},
pmc = {pmc:PMC4435704},
doi = {10.1002/acn3.189},
url = {https://pub.dzne.de/record/138289},
}